Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorun ...

– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive sleep apnea represents Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases – – Initiation of the trial anticipated in the first quarter of 2025 – RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Na ...

Group 1 - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone [1][3] - The company will report its financial results for the third quarter ended September 30, 2024, on November 11, 2024, after market close [1] - The initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor targeting cardiorenal conditions [3] Group 2 - A live webcast of the conference call regarding the financial results will be available on the company's Investor Relations page [2] - Contact information for investor relations and media relations is provided for further inquiries [4]

I covered Mineralys (NASDAQ: MLYS ) in April last year. It had a few things going that got me interested: It was a new IPO, had just published positive phase 2 data, and it had a strong board of directors. The stock took a deep About the TPT service Thanks for reading. At the Total Pharma Tracker, we offer the following :- ing Balance (millior Projected American Shared Revenue Backlog $250 $213 $200 $150 $106 $104 $101 $100 $50 $0 12/31/21 12/31/22 12/31/23 5/10/24 (projected*) Ending Balance Date *This cha ...

LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ: MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Mineralys released its second quarter 2024 financial results ...

"I am honored to join the Mineralys Board of Directors," stated Dr. Gold. "I look forward to working with the Company's executive team and fellow Board members to advance the treatment of cardiorenal metabolic disorders. There is significant potential with lorundrostat in offering a targeted treatment approach for hypertension and other diseases driven by dysregulated aldosterone." "The Board and I would like to express our collective gratitude to Olivier for his contributions and dedication to the Board. W ...

Core Insights - Mineralys Therapeutics has appointed Dr. Alexander M. Gold to its Board of Directors, effective June 13, 2024, to support the late-stage clinical development of lorundrostat for hypertension and related cardiorenal metabolic disorders [1][5][10] - Dr. Gold brings over 20 years of experience in biopharmaceuticals, having held executive roles in various companies and currently serving as Chief Medical Officer at a clinical-stage biotech firm [6][10] - The company also announced the resignation of Olivier Litzka from the Board, expressing gratitude for his contributions [3][10] Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), and other diseases linked to dysregulated aldosterone [12] - The primary product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor designed to treat uncontrolled hypertension and CKD [7][12] Product Development - Lorundrostat has shown a 70% reduction in plasma aldosterone concentration in hypertensive subjects and has a selectivity of 374-fold for aldosterone-synthase inhibition compared to cortisol-synthase inhibition [7] - In a Phase 2 trial, lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1966887 (Sta ...

Exhibit 99.1 Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • Pivotal Advance-HTN Trial – The ongoing Advance-HTN trial is evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to a standardized background treatment of two or three antihypertensive medications. • Pivotal Launch-HTN Phase 3 Trial – The Company's second ongoing pivotal trial of ...

Minji Kim, PhD. Chief Business Officer 20+ years of experience: Affamed, Jounce, Curis, Hoffman-LaRoche, Genentech Cindy Berejikian Balance sheet supports activities to execute on upcoming milestones | --- | --- | --- | |------------------------------------------------------------------|-------|-------| | | | | | | | | | Targeting Aldosterone in the Treatment of Cardiorenal Diseases | | | | Mar ch 2024 | | | We caution you that this presentation contains forward-looking statements. All statements other than ...